Merck Gaboxadol Submission Delayed Until Mid-2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.
You may also be interested in...
Merck R&D Renaissance To Continue With Three NDA Filings In 2007
During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.
Merck R&D Renaissance To Continue With Three NDA Filings In 2007
During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.